NCT05794581View on ClinicalTrials.gov

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

March 6, 2024

Study Completion Date

April 6, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

CT-868

CT-868

DRUG

Placebo

Placebo as SC Injection

DRUG

Victoza

Victoza as active comparator as SC Injection

Trial Locations (1)

91911

Carmot Clinical Research Unit 101, Chula Vista

Sponsors
All Listed Sponsors
lead

Carmot Therapeutics, Inc.

INDUSTRY